# Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma

> **NCT03995147** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **University of Chicago** · enrollment: 51 (actual)

## Conditions studied

- B Cell Lymphoma
- Lymphoma
- Lymphoma, B-Cell
- Diffuse Large B Cell Lymphoma
- High-grade B-cell Lymphoma

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** R-CHOP Protocol

## Key facts

- **NCT ID:** NCT03995147
- **Lead sponsor:** University of Chicago
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-08-29
- **Primary completion:** 2027-02-20
- **Final completion:** 2027-02-20
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2025-06-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03995147

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03995147, "Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03995147. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*